# Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In Children With Short Stature Secondary

> **NCT00174278** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 14 (—)

## Conditions studied

- Growth Hormone Deficiency
- Growth Retardation

## Interventions

- **DRUG:** Somatropin

## Key facts

- **NCT ID:** NCT00174278
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-02
- **Primary completion:** —
- **Final completion:** 2006-10
- **Target enrollment:** 14 (—)
- **Last updated:** 2008-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00174278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00174278, "Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In Children With Short Stature Secondary". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00174278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*